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 Summary
Aim: The basic assumption of the prevention of cervical cancer is to early detect and treat CIN (cervical intraepithelial 
neoplasia) as well as to prevent recurrence of neoplasia after therapy. This study involved comparison of the cytology 
test value and determination of HPV (human papilloma virus) DNA in women treated for CIN so as to find a sensitive 
and specific marker of disease recurrence. 
Methods: A group of 107 females after CIN treatment underwent 14-month follow-up and regular cytological and 
molecular evaluations. 
Results: Based on the follow-up data the recurrence of CIN was found in 9 females who despite effective therapy 
for the entire follow-up period were HPV positive. Evaluation of value of HR (high risk) - HPV DNA assay used to 
detect CIN showed its 100% sensitivity. 
Conclusion: The HR-HPV DNA assay is likely to be a valuable diagnostic tool facilitating more precise detection of 
recurrent neoplasia risk than cytological test alone. 
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extent	 –	 undoubtedly	 contributes	 to	 the	 decreased	 incidence	
of	 malignant	 neoplasms.	 It	 is	 noticeable	 especially	 in	 case	 of	
prophylaxis	of	cervical	cancer.	Cervical	cancer	is	the	second	most	
common	malignancy	in	females	worldwide	[1].	According	to	the	






rate	 in	 prophylactic	medical	 examinations	 [2].	 Documentation	








The	 aim	 of	 this	 study	 was	 to	 evaluate	 the	 value	 of	 HR-
HPV	DNA	assay	as	a	marker	of	recurrent	disease	in	females	after	
therapy	for	intraepithelial	cervical	neoplasia.	
Study population and design
The	 studied	 material	 included	 pap	 smears	 and	 tissue	
specimens	collected	 from	 the	cervix	 in	107	 females	diagnosed	
at	 the	 Cervical	 Pathophysiology	 Lab	 (CPL)	 of	 the	 University	
Clinical	 Obstetrics	 and	 Gynecological	 Hospital	 in	 Poznan	
between	 June	 2004	 and	October	 2006.	 Females	 were	 referred	
to	the	CPL	due	to	abnormal	pap	smears	(ASCUS,	LSIL,	HSIL)	
[7].	















from	 treatment	 onset	 to	 the	 first	 control	 of	 HR-HPV	 DNA.	
During	 the	 study	 conduct,	 both	 females	 and	 their	 partners	
declared	to	avoid	adulterous	sexual	intercourse	outside	marriage	
or	partnership.	
Human	 papilloma	 virus	 DNA	 was	 determined	 in	 the	
cellular	material	collected	from	the	cervical	disc	and	canal	using	
Amplicor	 HPV	 equipment.	 Amplicor	 HPV	 quality	 test	 used	
amplification	 of	 DNA	 segment	 by	 polymerase	 chain	 reaction	
(PCR)	and	hybridization	of	nucleic	acid	to	detect	genotypes	of	
high	risk	(high	risk	–	HR)	HPV	DNA:	16,	18,	31,	33,	35,	45,	51,	
52,	56,	58,	59	and	68	 in	cervical	canal	cells	drawn	 into	 liquid	
transport	medium.	
The	 Amplicor	 HPV	 test	 simultaneously	 performs	
amplification	of	PCR	of	 the	 searched	HPV	DNA	segment	 and	
B-globin	DNA	(cellular	control).	Amplification	mixture	(Master	
Mix)	contains	DNA	starter	pairs	for	13	high	risk	HPV	genotypes	
and	 B-globins.	 The	 detection	 of	 amplificated	 DNA	 fragments	
(amplicons)	 is	 carried	 out	 using	 oligonucleotide	 probe,	 which	




not	 raise	 interpretative	 doubts,	 having	 high	 clinical	 sensitivity	
and	specificity	of	96	%	[5].
 Streszczenie
Cel pracy: Podstawowym założeniem profilaktyki raka szyjki macicy, jest wczesne wykrycie i leczenie CIN a także 
zapobieganie nawrotom neoplazji po leczeniu. W pracy porównano wartość testu cytologicznego oraz oznaczania 
DNA HPV u kobiet leczonych z powodu CIN w celu poszukiwania czułego i swoistego markera nawrotu procesu 
chorobowego. 
Metoda: 14-miesięcznej obserwacji poddano 107 kobiet po leczeniu CIN, u których regularnie wykonywano ocenę 
cytologiczną i molekularną. 
Wyniki: Nawrót CIN wykryto u 9 obserwowanych kobiet, które mimo skutecznej terapii przez cały okres obserwacji 
były HPV pozytywne. Ocena wartości testu na obecność DNA HPV HR, użytego do wykrycia CIN wykazała 100% 
czułość tej metody. 
Wnioski: Test na obecność DNA HPV HR może być cennym narzędziem diagnostycznym, pozwalającym bardziej 
precyzyjnie niż badanie cytologiczne wykryć ryzyko nawrotu neoplazji. 
 Słowa kluczowe: HPV / neoplazja szyjki macicy / wznowa / CIN /      
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Results
The	 group	 of	 107	 women	 with	 confirmed	 cervical	
intraepithelial	 neoplasia	 of	 various	 severity	 were	 followed-
up:	 32	 patients	with	CIN	 I,	 43	with	CIN	 II	 and	 32	with	CIN	
III.	 Before	 the	 treatment,	 all	 subjects	 were	 HR-HPV	 positive.	
In	 91	 cases	 leep-loop	 conization	 was	 performed,	 10	 subjects	
underwent	cryotherapy	and	in	the	remaining	hysterectomy	was	
carried	 out.	At	 the	 first	 follow-up	 visit	 after	 end	 of	 treatment,	
47	 subjects	 (including	 17	with	CIN	 I,	 19	with	CIN	 II	 and	 11	
with	CIN	 III)	 had	 persistent	HR-HPV	 infection.	 Simultaneous	
cytological	examination	(ASCUS	or	LSIL)	was	abnormal	in	only	
5	 ones.	 Subsequent	 follow-up	 visits	 at	 6-8	 and	 12-14	months	




respectively.	 Based	 on	 the	 histological	 examinations	 over	 the	
entire	follow-up	period	the	recurrence	of	cervical	intraepithelial	
neoplasia	was	 found	 and	 confirmed	 in	9	 treated	 subjects	 (2	of	
them	were	already	present	during	the	follow-up	II	visit).	Among	
HPV	 negative	 patients,	 there	 was	 no	 recurrent	 CIN	 detected	
or	 diagnosed.	On	 the	 other	 hand,	 despite	 effective	 elimination	
of	 HR-HPV	 during	 treatment,	 9	 women	 were	 reinfected	 with	
HPV	by	their	sexual	partner	and	it	remained	till	 the	end	of	the	
follow-up	period.	The	results	of	statistical	analysis	of	all	women,	
without	 considering	 the	 division	 with	 respect	 to	 neoplasia	
severity,	demonstrated	100%	sensitivity	of	both	diagnostic	tests	
for	detecting	recurrent	CIN	at	follow-up	visits	II	and	III.	
Table I. Statistical analysis of viral and cytological test results for detecting cervical intraepithelial neoplasia recurrence at follow-up visits II and III  
after treatment in all participating subjects.  
Table II. Statistical analysis of viral and cytological test results for detecting cervical intraepithelial neoplasia recurrence at the follow-up visits I, II and III  
after treatment in subjects with CIN.  
Table III. Statistical analysis of viral and cytological test results for detecting cervical intraepithelial neoplasia recurrence at follow-up I, II and III visits  
after treatment in subjects with CIN III.  
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showed	significantly	higher	sensitivity	of	 this	 test	at	 follow-up	
visit	I	and	II	as	compared	to	the	one	of	PAP	test.	As	opposed	to	




















In	 spite	of	 secondary	exclusion	of	CIN	 treatment	 failure,	viral	
infection	persisted	in	these	4	patients	on	subsequent	follow-ups.	
Similar	 relationship	was	described	by	Nagai	 in	5	patients	with	














correlation	 between	 persistent	 neoplasia	 and	 chronic	 HPV	
infection	maintained	after	ineffective	treatment	showed	presence	
of	HR-HPV	DNA	 in	 82.8%	 of	women	 in	whom	CIN	 therapy	
failed	[11,	12].	
Our	 study	 involving	 107	 females	 treated	 for	 CIN	 and	
followed	 up	 from	 a	 period	 prior	 to	 the	 treatment	 and	 up	 to	 at	





an	 average	 risk	 of	 having	 recurrent	 CIN	 refers	 to	 about	 10%	
of	 women	 during	 2	 years	 after	 the	 end	 of	 therapy	 [14].	 This	
author	 observed	 765	 females	 who	 underwent	 ablation	 of	 CIN	

























the	 follow-up	had	 recurrent	 neoplasia,	which	was	 documented	
during	 the	 last	 third	 follow-up	 visit.	 Three	 cases	 of	 recurrent	




























negative	 females	 after	 CIN	 treatment	 had	 recurrent	 disease.	
Sarian	 et	 al.	 revealed	 that	 11	 of	 107	 subjects	 had	 recurrent	
cervical	intraepithelial	neoplasia	due	to	CIN	II	or	CIN	III	[15].	
Most	recurrent	diseases	involved	high-grade	neoplasia	confirmed	
in	 9	 women.	 The	 remaining	 two	 patients	 had	 medium-grade	
neoplasia.	Molecular	 tests	 for	HR-HPV	DNA	were	positive	 in	
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raises	a	great	 interest	 is	 the	comparison	of	 the	effectiveness	of	
HR-HPV	DNA	 test	 between	our	 studies	 and	 those	 of	Kreimer	
carried	out	in	the	comparable	study	groups.
The	 studies	 in	 previously	 treated	 CIN	 patients	 performed	
in	order	to	detect	and	diagnose	another	recurring	neoplasia,	the	
sensitivity	was	100%	both	with	respect	to	viral	and	cytological	
diagnostics	 of	 diagnostics	 used	 successively	 at	 the	 follow-up	
visits	II	and	III.	These	results	were	also	confirmed	by	Kreimer	
et	al.	who	demonstrated	100%	sensitivity	 for	both	 tests	during	
the	 first	 follow-up	 visit	 after	 treatment	 and	 its	 values	 for	
cytodiagnostics	 and	 molecular	 test	 detecting	 HR-HPV	 DNA	
which	 remained	 unchanged	 until	 the	 end	 of	 12-month	 follow-
up	 [20].	Number	of	 investigators	determined	 the	 sensitivity	of	
HR-HPV	DNA	test	as	100%	in	identifying	development	of	CIN	
in	women	 after	 neoplasia	 treatment	 [8,21].	Other	 studies	with	
analogous	examinations	results	showed	slightly	lower	sensitivity	







of	 recurrent	 CIN	 in	 females	 previously	 treated	 for	 neoplasia.	
It	 should	be	added	 that	 the	percentage	of	negative	 tests	 results	
for	 HR-HPV	DNA	 in	 treated	 healthy	 subjects	 increases	 along	















test,	 as	 a	 method	 of	 detection	 of	 recurrent	 CIN	 in	 previously	
treated	women,	 increases	 along	with	 time	 and	 seems	 to	 be	 of	




receiving	 effective	 treatment	 of	 CIN,	 who	 however	 were	 not	
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